Opinion|Videos|April 22, 2025
Comparing Biologic Treatment Patterns: Tildrakizumab vs Ustekinumab
Author(s)Aaron Farberg, MD
An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, persistence, adherence, and switching. Results showed favorable persistence and adherence. Provider administration may have influenced outcomes, impacting clinical decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is it so critical to have comparative studies with biologics FDA-approved for psoriasis?
- What were the objectives and methods of this study, and why is it important to analyze end points such as treatment discontinuation, persistence, adherence, and switching/reinitiation?
- What were the key results seen in terms of these key end points such as treatment discontinuation, persistence, adherence, and switching/reinitiation?
- Do you believe that having a health care provider–administered biologic impacted the results?
- Will the results from this study impact your clinical decision-making?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
3
Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates
4
Belantamab Mafodotin Can Help Fill Access Gaps in BCMA-Directed Myeloma Therapy: Hearn Jay Cho, MD, PhD
5
